|
Most Drugmakers Keep Postmarket Promises But Are Slow to Update FDA
While most drugmakers are good about keeping postmarket clinical trials on schedule, they don’t always file their required annual status reports on time, so the FDA often isn’t up to date on their progress, the agency says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives